Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations by Nordsmark, M et al.
It is well known that hypoxia is a common feature of solid tumours
and that neoplastic cells can survive under conditions of low
oxygenation as well as glucose deprivation (Vaupel et al, 1991).
Clinical and experimental studies have demonstrated that tumour
hypoxia causes resistance to radiation therapy, some chemo-
therapy agents, and also to surgery alone (Moulder and Rockwell,
1984; Durand, 1991; Höckel et al, 1996; Nordsmark et al, 1996a).
Recently, low apoptotic potential was demonstrated in hypoxic
highly aggressive human tumours (Höckel et al, 1999). These clin-
ical results suggested that hypoxia could induce malignant
progression, but is hypoxia really a driving force in neoplastic
transformation or is it simply a consequence of rapid tumour cell
proliferation accompanied with insufficient blood supply? In-vitro
studies have provided interesting results and shown that both
normal and cancer cells alter gene expression under hypoxic
conditions (Sutherland, 1996, Dachs and Tozer, 2000), supporting
the role of hypoxia in malignant progression. 
The tumour suppressor gene p53 induces apoptosis under
certain conditions and tumour hypoxia was found to select for p53
mutant tumour cells with diminished apoptotic potential (Graeber
et al, 1996). These findings led us to determine the prognostic
value of pre-treatment tumour oxygenation measurements on
survival after long-term follow-up and to investigate both tumour
oxygenation and p53 status in untreated human soft tissue
sarcomas in order to test whether hypoxic tumours might be
apoptotic incompetent due to mutations in the p53 gene. 
MATERIALS AND METHODS 
Patients 
The study involved 33 patients with primary extra-visceral soft
tissue sarcomas, referred to the Bone and Soft Tissue Sarcoma
Centre, Aarhus University Hospital, Denmark from February 1992
to May 1999. Using 3 eligibility criteria: (1) age ³ 18 years, (2)
tumour accessible for invasive oxygen electrode measurements
and (3) minimum tumour diameter of 2 cm, most of the 33 patients
matched a background population of 316 primary STS referred to
our centre between January 1979 and July 1993 (Vraa et al, 1998).
The local ethical committee gave approval and all patients gave
informed consent according to the Helsinki Declaration II. Median
age at the time of diagnosis was 54 years (range 23–87 years).
Sixteen were female, 12 were tobacco users, 18 did not use
tobacco and in 3 cases smoking history was not available. Two
patients had recurrent STS. Tumour sites were extremities (n =
26), back (n = 5) and abdomen and thorax (n = 2). 
Based on examinations of biopsy and/or surgical specimens the
group pathologist determined the histopathological diagnosis and
tumour grade as previously described (Jensen et al, 1991). 
Tumour oxygenation measurements 
Tumour oxygen partial pressure (pO2) was measured prior to treat-
ment using computerized polarographic oxygen-sensitive elec-
trodes (Eppendorf, Germany). This method has previously been
described in detail and found reliable and feasible in a whole range
of human tumours (Vaupel et al, 1991; Nordsmark et al, 1994).
Routine magnetic resonance imaging (MRI) provided anatomical
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details about the tumour localization, volume and depth below the
skin surface and this information was used during the pO2
measurement procedure to ensure that the length of each needle
electrode track was restricted to tumour tissue. Based on results
from a previous variance analysis a minimum of 3 electrode tracks
were required in order to reduce intra-tumour variability as
compared to tumour-to-tumour variability (Nordsmark et al,
1994). Among the 33 STS the median number of pO2 values 
was 184 (range 64–381). These measurements were sampled
along a median of 5 electrode tracks (range 3–7) per tumour.
Tumour oxygenation status was evaluated by the median tumour
pO2. From venous blood samples the total haemoglobin level 
was measured using a blood gas analyser (Radiometer OSM3,
Denmark). 
Some of the patients with Eppendorf data reported here 
have previously been published as a comparison between 
tumour oxygenation status and cell kinetic parameters involving
21 STS (Nordsmark et al, 1996b) and as a feasibility study of
tumour oxygenation assessment and 31PMRS involving 25 STS
(Nordsmark et al, 1997). 
p53 mutation analysis 
Biopsy material was available for p53 mutation analysis in 31
STS. In the remaining 2 cases only paraffin-embedded tissue was
available but it was not possible to extract enough tissue for
analysis. DNA was successfully extracted from paraffin-
embedded sections (n = 2) (QIAamp DNA Mini Kit, Qiagen,
Valencia, CA) or frozen biopsies (n = 29) (Puragene DNA
Isolation Kit, Gentra Systems, Minneapolis, MN). The entire
coding region and all exon/intron boundaries of p53 were analysed
by denaturing gradient gel electrophoresis (DGGE). Twelve sets of
primers for amplification and DGGE analysis of exons 2–11
(including overlapping amplicons for exons 4 and 5) have been
described previously (Guldberg et al, 1997). Amplification reac-
tions were carried out by 38 rounds of thermal cycling (94˚C for
20 s, 62˚C for 20 s, and 72˚C for 20 s) in final volumes of 15 ml
containing 10 mM Tris/HCl (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 0.02% gelatine, 0.2 mM cresol red, 12% sucrose, 5%
DMSO, 100 mM of each dNTP, 0.6 mM of each primer, 100 ng
DNA, and 0.5 U AmpliTaq DNA polymerase (Applied Biosystems,
Foster City, CA). For DGGE analysis, PCR products were run on
6% polyacrylamide gels containing various gradients of urea and
formamide (100% denaturant consisted of 7 M urea and 40%
formamide). As a modification to a previous approach (Guldberg
et al, 1997), the gradient ranges were narrowed and adapted to
each exon to increase the separation between mutant and wild-type
alleles. The gradient ranges were for exon 5: 40–80%, for exon 6:
25–65%, for exons 7 and 8: 35–75%, and for exon 9: 20–60%,
respectively. The gels were run for 1050 V hours in 1 ´ TAE buffer
at a constant temperature of 58˚C. Following electrophoresis, 
gels were stained in 1 ´ TAE buffer containing 2 mg per ml
ethidium bromide and analysed under UV-transillumination.
Mutant heteroduplex or homoduplex bands were excised and re-
amplified as described (Guldberg et al, 1997). Sequencing of PCR
products was performed with the BigDye DyeTerminator Cycle
Sequencing Kit and analysed on an ABI 310 (Applied Biosystems,
Foster City, CA). 
Treatment and follow up 
Among the 33 patients the 2 STS with recurrent disease were not
included in the survival analysis. Of the remaining 31 patients with
primary STS 3 were not evaluated due to incomplete treatment 
(n = 1), and breast cancer (n = 2). This leaves 28 cases for survival
analysis of tumour oxygenation as a prognostic marker. Twelve
patients were treated by surgery alone using wide margins and limb
conservation as previously described (Vraa et al, 1998). Adjuvant
radiation therapy (RT) was given as preoperative RT to 11 patients
and as postoperative RT in 5 cases. The radiation doses were 50 Gy
in 25 fractions (n = 15) and 60 Gy in 30 fractions (n = 1). 
The initial follow-up included physical examination and chest
X-ray 2 months after the end of treatment and subsequent controls
were done regularly until 5 years. In individual cases consultation
was done more often than routinely scheduled. Local recurrence or
distant metastases were fully evaluated and if possible patients
with relapse were offered either surgery or chemotherapy. The
treatment endpoints were overall survival and disease-specific
survival defined as death following treatment, death due to STS, or
death from other diseases with tumour or metastasis. Tumour
control was defined as complete and persistent regression and no
sign of disseminated disease. Follow-up was evaluated from the
first day of treatment until December 1, 1999 or until death. The
median follow-up for all patients was 74 months (range 13–83)
with a minimum follow-up of 13 months among the survivors. 
Statistical analysis 
Disease-specific and overall 5-year actuarial survival was evalu-
ated by Kaplan–Meier plots and differences were estimated by the
log-rank analysis using the BMDP statistical program. The Cox
proportional hazard model was used for univariate analysis of
median tumour pO2 as a prognostic parameter. Comparisons
between patient and tumour characteristics among survivors and
the dead, and among patients with hypoxic versus well-
oxygenated tumours was done by the Wilcoxon signed rank test or
Chi-square test. In all cases a 2-sided significance level of 5% was
used. 
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Figure 1 Median tumour pO2 from 33 patients plotted on a cumulative
frequency scale. Open symbols (l l) indicate patients who have died and
filled symbols (l) patients alive. Arrows indicate the 6 tumours with p53
mutations RESULTS 
Wild-type p53 was found in 25 tumours and mutations in 6 cases
with primary STS. The presumed functional change in each mutation
is listed in Table 1. Figure 1 shows the median tumour pO2 of 33
individual tumours plotted on a frequency scale to illustrate the
tumour-to-tumour variability and the relationship to p53 status and
survival. No association was found between the median tumour pO2
and p53 status. Tumour oxygenation status varied between all 33 soft
tissue sarcomas with an overall median = 19 mmHg (range 1–58
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Table 1 Characterization of p53 mutations 
Pt Mutation Exon Structural change Presumed functional change 
1 g.13429-13469dela 6 Splice deficiency Splice deficiency, loss of function 
2 c.880G>Tb 8 E294X Nonsense mutation, loss of function 
3 c.659A>G 6 Y220C Missense mutation in the short loop between the S7 and S8 strand,c loss of function
(transactivation activityd) 
4 c.469G>T 5 V157F Missense mutation in the S4 strandc, loss of function (transactivation activitye) 
5 c.625-626del 6 R209delX214 Frameshift mutation, loss of function 
6 c.844C>G 8 R282G Missense mutation in the H2 helix of the LSH motifc, loss of functionc
ag.denotes genomic number (AC no. U94788). bc. denotes cDNA number (AC no M14694). cAccording to Cho et al (1994). dAccording to Di Como and Prives
(1998). eAccording to Obata et al (2000). 
Table 2 Survival status and patient and tumour characteristics 
All Alive Dead
median (range) median (range) median (range)  P value 
No of patients 28 16 12 
Age (years) 59 (30–87) 50 (33–80) 67 (30–87) NS 
Sex (male/female) 15/13 8/8 7/5 NS 
Hb total (mmol l–1) 8.6 (5.5–9.7) 8.7 (7.4–9.7) 8.4 (5.5–9.6) NS 
Median tumour pO2 (mmHg) 19 (1–58) 24 (3–58) 10 (1–32) NS* 
Tumour size (cm) 10 (3–20) 9 (3–20) 10 (4–20) NS 
Functional p53 mutation 6 3 3 
Histopathology 
Grade I–II 6 6 0 
Grade III 22 10 12 
Treatment 
Surgery 12 5 7 
Adjuvant RT 16 11 5 
NS = not significant; *P = 0.08. 
Table 3 Oxygenation status and patient and tumour characteristics 
All Well-oxygenated Hypoxic
median (range) median (range) median (range)  P value 
No of patients 28 14 14 
Age (years) 59 (30–87) 52 (33–87) 64 (30–81) NS 
Sex (male/female) 15/13 5/9 10/4 NS 
Hb total (mmol l–1) 8.6 (5.5–9.7) 8.7 (7.6–9.4) 8.2 (5.5–9.7) NS 
Median tumour pO2 (mmHg) 19 (1–58) 30 (21–58) 8 (1–18) <0.01 
Tumour size (cm) 10 (3–20) 8 (3–20) 10 (4–20) NS 
Functional p53 mutation 6 4 2 
Histopathology 
Grade I–II 6 5 1 
Grade III 22 9 13 
Treatment 
Surgery 12 5 7 
Adjuvant RT 16 9 7 
NS = not significant. mmHg). 
At the time of analysis 16 patients were still alive. Ten died
from STS with pulmonary metastasis, 1 from stroke and 1 from
cardiac disease. Among the survivors 10 patients completed the
planned 5 year period of follow-up and none of these had any
sign of recurrence. One patient with distant metastasis is still
alive 4 years after time of relapse. 12 patients died with an
overall median pO2 of 10 mmHg (range 1–32 mmHg) as
compared to 24 mmHg (range 3–58 mmHg) among the 16
survivors (Wilcoxon signed rank test, P = 0.12). The groups
of survivors and non-survivors were equally distributed with
respect to age, sex, tumour size, treatment strategy, haemoglobin
and smoking history, whereas histological grade I and II tumours
were more frequent among survivors. Six among 28 (19%)
expressed mutant p53 and 3 (10%) of these died, whereas 22
among 28 (79%) of patients had wild-type p53 and 11 (39%) of
these died. Some of these parameters are listed in Table 2.
Identical tumour characteristics were compared according to
oxygenation status (Table 3). The overall median among the 28
cases amenable for survival analysis was 19 mmHg. Tumours
above a median pO2 of 19 mmHg were classified as well-
oxygenated and ≤19 mmHg as hypoxic. It was seen that 
well-oxygenated tumours were slightly more common among
females. Interestingly, all 6 patients with grade I–II tumours were
alive by the time of analysis and only 1 of these tumours was
hypoxic (median pO2 ≤19 mmHg), whereas grade III tumours
(n = 22) represented both hypoxic (n = 13) and well-oxygenated
(n = 9) tumours. Tumour grade reached statistical significance as
a prognostic variable in a univariate analysis with overall
survival as the endpoint (P = 0.03). Also, the median tumour pO2
was a significant prognostic factor (P = 0.01) in a univariate
analysis with a decrease in median pO2 related to a decrease in
overall survival probability. Using a Kaplan–Meier analysis
patients were stratified into well oxygenated or hypoxic based on
overall median pO2 (Figure 2). The hypoxic group had a signifi-
cantly poorer disease-specific survival of 40% compared to 77%
for well-oxygenated tumours (P = 0.05). Likewise patients with
hypoxic tumours had a significantly poorer overall survival prob-
ability of 28% versus 77% (P = 0.01) at 5 years. 
DISCUSSION 
The current study showed that hypoxic primary STS had a poorer
overall survival rate after 5 years of follow-up. Patients received
pre- or post-operative RT or surgery alone and were followed for a
median of 6 years. This result is in agreement with a previous
report in primary STS by Brizel et al where the follow up was rela-
tively short (median 1 year) and where the endpoint was freedom
from metastases (Brizel et al, 1996). Similar results were obtained
from a range of studies in uterine cervix carcinomas and squamous
cell carcinoma of the head and neck (Hockel et al, 1996;
Nordsmark et al, 1996a; Fyles et al, 1998; Adam et al, 1999; Brizel
et al, 1999; Knocke et al, 1999; Stadler et al, 1999; Nordsmark and
Overgaard, 2000; Rudat et al, 2000; Sundfor et al, 2000). 
It was suggested that hypoxia could induce malignant progres-
sion in human cervix carcinoma (Höckel et al, 1996) and soft
tissue sarcoma (Brizel et al, 1996). But what is the clinical and
experimental evidence that hypoxia induces malignant progres-
sion? Certainly, there is increasing evidence that treatment failure
among patients with hypoxic tumours is not an effect of radiation-
resistant hypoxic cells alone but whether this is related to malig-
nant progression still remains to be proven. The experimental
in-vitro data are encouraging. An increasing number of studies
have reported that different genes are up- or down-regulated during
hypoxia and fluctuating oxygenation (for review Dachs and Tozer,
2000). Interestingly, melanoma cells in-vitro progressed from a
benign to a highly malignant phenotype after exposure to sequen-
tial rounds of hypoxia (Stackpole et al, 1994). 
The clinical data available are limited in number of patients and
provide more indirect evidence that hypoxia may induce metas-
tases. We previously found an inverse relationship between the
tumour cell potential doubling time (Tpot) and the median tumour
p53, hypoxia and treatment outcome in soft tissue sarcomas 1073
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Figure 2 Tumour oxygenation was evaluated by the overall median tumour pO2. Tumours with median pO2 above 19 mmHg were classified as well-
oxygenated and below or equal to 19 mmHg as hypoxic. 5 year disease-specific and overall survival rates were estimated by actuarial tumour control probability
using Kaplan–Maier estimates. Patients with the most hypoxic tumours had a statistically significant poorer disease specific survival probability (Figure 2A; 
P = 0.05) and poorer overall survival probability (Figure 2 B; P = 0.01) when compared to well oxygenated tumours. pO2 in human soft tissue sarcomas and we hypothesized that
high proliferation rate was confined to more hypoxic tumours
(Nordsmark et al, 1996b). In hypoxic human cervix carcinomas
low apoptotic index was associated with highly aggressive
tumours (Höckel et al, 1999). Hypoxia inducible factor 1 (HIF-1a)
was up-regulated in a range of human tumours (Zohng et al, 1999)
and it was shown that over-expression of HIF-a was a marker for
poor prognosis in early stage uterine cervix carcinoma (Birner 
et al, 2000). HIF-1a is an O2-regulated subunit of a more complex
protein that can be assessed by immunohistochemistry. 
Experimental studies have suggested that apoptotic cell kill was
compromised by hypoxia in mutant p53 cells. Graeber et al (1996)
showed that hypoxia-induced apoptosis in oncogenically trans-
formed cells and loss of the p53 suppressor gene made cells less
susceptible to hypoxia-induced cell death. They also demonstrated
that hypoxia co-localized with apoptosis in-vivo (Graeber et al,
1996). We tested this hypothesis in human STS but found no asso-
ciation between mutant p53 and hypoxia, which was in agreement
with the results obtained by Birner et al (2000). These results can
of course reflect the biological true situation but other factors may
play a role. The current study was small in terms of the number of
patients and therefore the statistical power was poor, hence our
results are to be considered as hypothesis-generating. The patient
number in the Birner study was higher but a weakness of that study
was that they measured p53 protein by immunohistochemistry and
using that technique certain forms of mutant p53 can be missed.
There is general agreement that mutant p53 is an indicator for poor
prognosis in some human cancers (Klijn, 1997), but it is also well
known that cell control can be interrupted in cases where wild-
type p53 may not be functional due to mutations in other genes
(Vogelstein et al, 2000). 
Histopathological grade is a classical prognostic indicator for
survival in STS (Jensen et al, 1991; Vraa et al, 1998). We found
that all 6 patients with grade I or II tumours were alive and 5 of
those had less hypoxic tumours. Histopathological grade is in
general poorly reported in studies that have evaluated the prog-
nostic value of oxygenation status. One study in breast cancer
reported that 6 out of 7 cases with lower-grade tumours were 
well oxygenated with a median tumour pO2 above 22 mmHg
(Hohenberger et al, 1998). Two studies in squamous cell carci-
nomas of either uterine cervix or head and neck found no correla-
tion between hypoxia and histological grade (Höckel et al, 1996;
Nordsmark et al, 1996a). Even if multivariate analyses were
performed none of the trials had sufficient statistical power to test
the prognostic value of tumour hypoxia and histological grade on
survival. In addition, the current study did not show that hypoxia
predisposes to metastases independent of grade. 
In conclusion, hypoxia was an indicator for poor prognosis in
soft tissue sarcomas as patients with the most hypoxic tumours
were associated with a poorer disease-specific and overall survival
probability. Lower-grade STS were in general well-oxygenated.
Finally, hypoxic tumours were not characterized by mutations in
the p53 gene. 
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